10x Genomics, Inc. (NASDAQ:TXG) Q4 2022 Earnings Conference Call February 15, 2023 4:30 PM ET
Company Participants
Cassie Corneau - Head, Investor Relations & Strategic Finance
Serge Saxonov - Chief Executive Officer & Co-Founder
Justin McAnear - Chief Financial Officer
Conference Call Participants
Dan Brennan - Cowen
Dan Arias - Stifel
Tejas Savant - Morgan Stanley
Patrick Donnelly - Citigroup
Julia Qin - J.P. Morgan
Kyle Mikson - Canaccord Genuity
Matt Larew - William Blair
Michael Ryskin - Bank of America
Matthew Sykes - Goldman Sachs
Justin Bowers - Deutsche Bank
John Sourbeer - UBS
Operator
Good afternoon. Thank you for attending today's 10x Genomics Fourth Quarter and Full Year 2022 Earnings Conference Call. My name is Bethany, and I will be the moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. [Operator Instructions]
I would now like to pass the conference over to our host, Cassie Corneau with 10x Genomics. Please go ahead.
Cassie Corneau
Thank you, and good afternoon, everyone.
Earlier today, 10x Genomics released financial results for the fourth quarter and full year ended December 31, 2022. If you have not received this news release or if you would like to be added to the company's distribution list, please send an email to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company's website 10xgenomics.com for at least 45 days following this call.
Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements.
Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release 10x Genomics issued today and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.
Joining the call today are Serge Saxonov, our CEO and Co-Founder; and Justin McAnear, our Chief Financial Officer.
With that, I will now turn the call over to Serge.